Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 27, 2026 Filed Feb 18, 2026 00:00 UTC |
Casper Joseph MichaelChief Operating Officer
|
GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001437749-26-004426 · rdgdoc.xml · derivative · entry 1 Casper Joseph Michael · CIK 0002106955 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-01-27 F1 · price: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 33.3% of the Options shall vest on June 1, 2026, 33.3% shall vest on December 1, 2026, and the remaining 33.3% shall vest on December 1, 2027. F1 · derivative.exercise_date: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 33.3% of the Options shall vest on June 1, 2026, 33.3% shall vest on December 1, 2026, and the remaining 33.3% shall vest on December 1, 2027. Read SEC document |
| April 09, 2025 Filed Sep 10, 2025 15:35 UTC |
McBride DennisDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001415889-25-024083 · form4-09102025_070927.xml · derivative · entry 1 McBride Dennis · CIK 0002028250 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-04-09 F1 · price: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer. F1 · derivative.exercise_date: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer. Read SEC document |
| April 09, 2025 Filed Sep 10, 2025 15:34 UTC |
Flynn Patrick JohnDirector
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001415889-25-024081 · form4-09102025_070918.xml · derivative · entry 1 Flynn Patrick John · CIK 0001864871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-04-09 F1 · price: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer. F1 · derivative.exercise_date: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer. Read SEC document |
| April 09, 2025 Filed Sep 10, 2025 15:36 UTC |
Javitt Jonathan CDirector · Chairman and Chief Scientist · 10% owner
|
GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001415889-25-024084 · form4-09102025_070903.xml · derivative · entry 1 Javitt Jonathan C · CIK 0001303782 · Director · Chairman and Chief Scientist · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2035-04-09 F1 · price: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 1/3 of the Options shall vest on the first anniversary of the grant date, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to continued F1 · derivative.exercise_date: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 1/3 of the Options shall vest on the first anniversary of the grant date, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to continued Read SEC document |
| April 09, 2025 Filed Sep 10, 2025 15:35 UTC |
Hurvitz ChaimDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001415889-25-024082 · form4-09102025_070956.xml · derivative · entry 1 Hurvitz Chaim · CIK 0001630542 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-04-09 F1 · price: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer. F1 · derivative.exercise_date: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 17:00 UTC |
ABRAMS MICHAEL SChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001415889-25-003585 · form4-02112025_050201.xml · derivative · entry 1 ABRAMS MICHAEL S · CIK 0001497702 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-02-07 F1 · derivative.exercise_date: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest in three equal annual installments beginning on February 7, 2026. Read SEC document |
| December 17, 2024 Filed Dec 18, 2024 08:27 UTC |
Javitt Jonathan CDirector · Chairman and Chief Scientist · 10% owner
|
PurchaseCommon Stock | 40,000 | $1.17 | $46,800.00 |
DisclosureSEC source: 0001415889-24-029694 · form4-12182024_011233.xml · nonDerivative · entry 1 Javitt Jonathan C · CIK 0001303782 · Director · Chairman and Chief Scientist · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,634 Read SEC document |
| August 30, 2023 Filed Sep 11, 2023 09:19 UTC |
Gorovitz AaronDirector
|
PurchaseCommon Stock, par value $0.001 per share | 35,000 | $0.32 | $11,196.50 |
DisclosureSEC source: 0001415889-23-013139 · form4-09112023_010928.xml · nonDerivative · entry 1 Gorovitz Aaron · CIK 0001864536 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 105,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected. F2 · balance_after: Consists of (i) 8,336 shares of Common Stock held by Samuel David Gorovitz 2017 Irrevocable Trust, (ii) 8,336 shares of Common Stock held by Jeremy Paul Gorovitz 2017 Irrevocable Trust, (iii) 8,336 shares of Common Stock held by Marisa Shey Gorovitz 2017 Irrevocable Trust, (iv) 51,678 shares of Common Stock held by Elizabeth Gorovitz. Aaron Gorovitz is the trustee of the Samuel David Gorovitz 2017 Irrevocable Trust, the Jeremy Paul Gorovitz 2017 Irrevocable Trust, and the Marisa Shey Gorovitz 2017 Irrevocable Trust. Elizabeth Gorovitz is the wife of Aaron Gorovitz; Read SEC document |
| August 30, 2023 Filed Sep 11, 2023 09:15 UTC |
Hurvitz ChaimDirector
|
PurchaseCommon Stock, par value $0.001 per share | 70,000 | $0.29 | $20,125.00 |
DisclosureSEC source: 0001415889-23-013137 · form4-09112023_010907.xml · nonDerivative · entry 1 Hurvitz Chaim · CIK 0001630542 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 570,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected. Read SEC document |
| August 23, 2023 Filed Aug 24, 2023 12:14 UTC |
Javitt Jonathan CDirector · Chief Scientist · 10% owner
|
PurchaseCommon Stock | 100,000 | $0.33 | $33,000.00 |
DisclosureSEC source: 0001104659-23-094815 · tm2324394-3_4seq1.xml · nonDerivative · entry 1 Javitt Jonathan C · CIK 0001303782 · Director · Chief Scientist · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 446,332 Read SEC document |
| August 22, 2023 Filed Aug 23, 2023 09:24 UTC |
Javitt Jonathan CDirector · Chief Scientist · 10% owner
|
PurchaseCommon Stock | 200,000 | $0.32 | $64,400.00 |
DisclosureSEC source: 0001104659-23-094406 · tm2324394-1_4seq1.xml · nonDerivative · entry 1 Javitt Jonathan C · CIK 0001303782 · Director · Chief Scientist · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,332 Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 07:09 UTC |
VAN VOORHEES SETHCHIEF FINANCIAL OFFICER
|
PurchaseCommon Stock, par value $0.001 per share | 30,000 | $1.10 | $33,000.00 |
DisclosureSEC source: 0001415889-22-012652 · form4-12192022_121236.xml · nonDerivative · entry 1 VAN VOORHEES SETH · CIK 0001284934 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,337 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.09 to $1.11. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 12:14 UTC |
Willard Stephen HDirector · CHIEF EXECUTIVE OFFICER
|
PurchaseCommon Stock, par value $0.001 per share | 50,000 | $1.17 | $58,500.00 |
DisclosureSEC source: 0001415889-22-012654 · form4-12192022_121215.xml · nonDerivative · entry 1 Willard Stephen H · CIK 0001325232 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.09 to $1.20. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected. Read SEC document |
| December 14, 2022 Filed Feb 14, 2023 17:14 UTC |
Javitt Jonathan CDirector · 10% owner
|
GiftCommon Stock, par value $0.001 per share | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002500 · form5-02142023_100203.xml · nonDerivative · entry 1 Javitt Jonathan C · CIK 0001303782 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 14,468,329 F1 · kind: Donation of 300,000 shares from the Jonathan Javitt Living Trust to the Jonathan Javitt Donor Advised Fund. F2 · price: Charitable Transfer F3 · balance_after: Consists of (i) 12,599,997 shares of common stock held by the Jonathan Javitt Living Trust, (ii) 1,422,000 shares of common stock held by The Javitt 2012 Irrevocable Dynasty Trust, (iii) 146,332 shares of common stock held by Jonathan Javitt individually and (iv) 300,000 held by the Jonathan Javitt Donor Advised Fund. Jonathan Javitt is the trustee of the Jonathan Javitt Living Trust, the Grantor of The Javitt 2012 Irrevocable Dynasty Trust and the donor and primary advisor of the Jonathan Javitt Donor Advised Fund. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 16:33 UTC |
Javitt Jonathan CDirector · 10% owner
|
SaleCommon Stock, par value $0.001 per share | 400,000 | $1.00 | $400,000.00 |
DisclosureSEC source: 0001415889-22-012324 · form4-12092022_091256.xml · nonDerivative · entry 1 Javitt Jonathan C · CIK 0001303782 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 12,899,997 F1 · acquired: Private sale pursuant to an option granted by the Reporting Person in 2017 in support of a financing for NeuroRx, Inc. Purchaser has agreed to hold the shares for a period of one year. F2 · ownership.nature: Held by the Jonathan Javitt Living Trust. The Reporting Person is a trustee of the Trust. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 19:29 UTC |
Javitt Daniel C.10% owner
|
Salecommon stock | 8,441 | $1.50 | $12,700.33 |
DisclosureSEC source: 0000880984-22-000017 · primary_doc.xml · nonDerivative · entry 2 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 9,634,793 F1 · kind: Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022. F2 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 19:29 UTC |
Javitt Daniel C.10% owner
|
Salecommon stock | 13,730 | $1.50 | $20,651.29 |
DisclosureSEC source: 0000880984-22-000017 · primary_doc.xml · nonDerivative · entry 1 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 9,643,234 F1 · kind: Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022. F2 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| November 28, 2022 Filed Nov 29, 2022 07:00 UTC |
Flynn Patrick JohnDirector
|
PurchaseCommon Stock, par value $0.001 per share | 1,750 | $1.25 | $2,187.50 |
DisclosureSEC source: 0001415889-22-011810 · form4-11292022_071101.xml · nonDerivative · entry 5 Flynn Patrick John · CIK 0001864871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Read SEC document |
| November 28, 2022 Filed Nov 29, 2022 07:00 UTC |
Flynn Patrick JohnDirector
|
PurchaseCommon Stock, par value $0.001 per share | 2,500 | $1.24 | $3,100.00 |
DisclosureSEC source: 0001415889-22-011810 · form4-11292022_071101.xml · nonDerivative · entry 4 Flynn Patrick John · CIK 0001864871 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 40,209 F4 · ownership.nature: Held by the Lindsay Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee. Read SEC document |
| November 28, 2022 Filed Nov 29, 2022 07:00 UTC |
Flynn Patrick JohnDirector
|
PurchaseCommon Stock, par value $0.001 per share | 2,500 | $1.25 | $3,125.00 |
DisclosureSEC source: 0001415889-22-011810 · form4-11292022_071101.xml · nonDerivative · entry 3 Flynn Patrick John · CIK 0001864871 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 37,709 F3 · ownership.nature: Held by the Lindsay Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee. Read SEC document |
| November 28, 2022 Filed Nov 29, 2022 07:00 UTC |
Flynn Patrick JohnDirector
|
PurchaseCommon Stock, par value $0.001 per share | 2,500 | $1.25 | $3,125.00 |
DisclosureSEC source: 0001415889-22-011810 · form4-11292022_071101.xml · nonDerivative · entry 2 Flynn Patrick John · CIK 0001864871 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 40,209 F2 · ownership.nature: Held by the Whitney Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee. Read SEC document |
| November 28, 2022 Filed Nov 29, 2022 07:00 UTC |
Flynn Patrick JohnDirector
|
PurchaseCommon Stock, par value $0.001 per share | 2,500 | $1.25 | $3,125.00 |
DisclosureSEC source: 0001415889-22-011810 · form4-11292022_071101.xml · nonDerivative · entry 1 Flynn Patrick John · CIK 0001864871 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 37,709 F1 · ownership.nature: Held by the Whitney Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee. Read SEC document |
| November 25, 2022 Filed Nov 28, 2022 07:42 UTC |
VAN VOORHEES SETHCHIEF FINANCIAL OFFICER
|
PurchaseCommon Stock, par value $0.001 per share | 7,021 | $1.11 | $7,793.31 |
DisclosureSEC source: 0001415889-22-011778 · form4-11282022_121119.xml · nonDerivative · entry 3 VAN VOORHEES SETH · CIK 0001284934 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · Shares purchased though 401(k) plan Disclosed balance after: 16,377 Read SEC document |
| November 25, 2022 Filed Nov 28, 2022 07:42 UTC |
VAN VOORHEES SETHCHIEF FINANCIAL OFFICER
|
PurchaseCommon Stock, par value $0.001 per share | 600 | $1.10 | $660.00 |
DisclosureSEC source: 0001415889-22-011778 · form4-11282022_121119.xml · nonDerivative · entry 2 VAN VOORHEES SETH · CIK 0001284934 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · Shares purchased though 401(k) plan Disclosed balance after: 9,316 Read SEC document |
| November 25, 2022 Filed Nov 28, 2022 07:42 UTC |
VAN VOORHEES SETHCHIEF FINANCIAL OFFICER
|
PurchaseCommon Stock, par value $0.001 per share | 8,716 | $1.12 | $9,761.92 |
DisclosureSEC source: 0001415889-22-011778 · form4-11282022_121119.xml · nonDerivative · entry 1 VAN VOORHEES SETH · CIK 0001284934 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · Shares purchased though 401(k) plan Disclosed balance after: 8,716 Read SEC document |
| November 25, 2022 Filed Dec 19, 2022 07:08 UTC Amendment |
VAN VOORHEES SETHCHIEF FINANCIAL OFFICER
|
PurchaseCommon Stock, par value $0.001 per share | 7,021 | $1.11 | $7,793.31 |
DisclosureSEC source: 0001415889-22-012650 · form4a-12192022_121206.xml · nonDerivative · entry 3 VAN VOORHEES SETH · CIK 0001284934 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,337 F3 · balance_after: Total number of shares held is reduced by 40 shares to correct an arithmetic error in the original Form 4. F4 · ownership.direct: The form of ownership has been changed from Indirect to Direct. The original Form 4 stated that these shares were purchased though a 401(k) plan. This Form 4/A is being filed to correct this error. Read SEC document |
| November 25, 2022 Filed Dec 19, 2022 07:08 UTC Amendment |
VAN VOORHEES SETHCHIEF FINANCIAL OFFICER
|
PurchaseCommon Stock, par value $0.001 per share | 600 | $1.10 | $660.00 |
DisclosureSEC source: 0001415889-22-012650 · form4a-12192022_121206.xml · nonDerivative · entry 2 VAN VOORHEES SETH · CIK 0001284934 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,316 F2 · ownership.direct: The form of ownership has been changed from Indirect to Direct. The original Form 4 stated that these shares were purchased though a 401(k) plan. This Form 4/A is being filed to correct this error. Read SEC document |
| November 25, 2022 Filed Dec 19, 2022 07:08 UTC Amendment |
VAN VOORHEES SETHCHIEF FINANCIAL OFFICER
|
PurchaseCommon Stock, par value $0.001 per share | 8,716 | $1.12 | $9,761.92 |
DisclosureSEC source: 0001415889-22-012650 · form4a-12192022_121206.xml · nonDerivative · entry 1 VAN VOORHEES SETH · CIK 0001284934 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,716 F1 · ownership.direct: The form of ownership has been changed from Indirect to Direct. The original Form 4 stated that these shares were purchased though a 401(k) plan. This Form 4/A is being filed to correct this error. Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 17:58 UTC |
Hurvitz ChaimDirector
|
PurchaseCommon Stock | 40,408 | $1.10 | $44,448.80 |
DisclosureSEC source: 0000950142-22-003233 · es220307158_4-hurvitz.xml · nonDerivative · entry 3 Hurvitz Chaim · CIK 0001630542 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 F3 · price: The price reported above reflects the weighted average purchase price per share of the Common Stock. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Read SEC document |
| November 18, 2022 Filed Nov 23, 2022 16:09 UTC Amendment |
Hurvitz ChaimDirector
|
PurchaseCommon Stock | 40,408 | $1.10 | $44,448.80 |
DisclosureSEC source: 0000950142-22-003250 · es220307715_4a-hurvitz.xml · nonDerivative · entry 3 Hurvitz Chaim · CIK 0001630542 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 F3 · price: The original Form 4 disclosed that the price reported in Column 4 is a weighted average price. This Form 4/A is being filed to amend such information. The shares were purchased in a single transaction at $1.10. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 19:05 UTC |
Javitt Daniel C.10% owner
|
Salecommon stock | 33,018 | $1.05 | $34,744.84 |
DisclosureSEC source: 0000880984-22-000015 · primary_doc.xml · nonDerivative · entry 2 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 9,656,964 F1 · kind: Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022. F2 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 17:58 UTC |
Hurvitz ChaimDirector
|
PurchaseCommon Stock | 171,780 | $1.08 | $185,522.40 |
DisclosureSEC source: 0000950142-22-003233 · es220307158_4-hurvitz.xml · nonDerivative · entry 2 Hurvitz Chaim · CIK 0001630542 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,592 F2 · price: The price reported above reflects the weighted average purchase price per share of the Common Stock. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected. Read SEC document |
| November 17, 2022 Filed Nov 23, 2022 16:09 UTC Amendment |
Hurvitz ChaimDirector
|
PurchaseCommon Stock | 171,780 | $1.08 | $185,522.40 |
DisclosureSEC source: 0000950142-22-003250 · es220307715_4a-hurvitz.xml · nonDerivative · entry 2 Hurvitz Chaim · CIK 0001630542 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,592 F2 · price: The price reported in Column 4 is a weighted average price. The original Form 4 did not disclose the range of prices that the shares were purchased pursuant to this transaction. This Form 4/A is being filed to include such ranges. These shares were purchased in multiple transactions at prices ranging from $1.10 to $1.01. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 19:05 UTC |
Javitt Daniel C.10% owner
|
Salecommon stock | 133,719 | $1.02 | $136,393.38 |
DisclosureSEC source: 0000880984-22-000015 · primary_doc.xml · nonDerivative · entry 1 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 9,689,982 F1 · kind: Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022. F2 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| November 16, 2022 Filed Nov 21, 2022 17:58 UTC |
Hurvitz ChaimDirector
|
PurchaseCommon Stock | 287,812 | $0.99 | $284,933.88 |
DisclosureSEC source: 0000950142-22-003233 · es220307158_4-hurvitz.xml · nonDerivative · entry 1 Hurvitz Chaim · CIK 0001630542 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,812 F1 · price: The price reported above reflects the weighted average purchase price per share of common stock (the "Common Stock"), of NRx Pharmaceuticals, Inc. (the "Issuer"). The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected. Read SEC document |
| November 16, 2022 Filed Nov 23, 2022 16:09 UTC Amendment |
Hurvitz ChaimDirector
|
PurchaseCommon Stock | 287,812 | $0.99 | $284,933.88 |
DisclosureSEC source: 0000950142-22-003250 · es220307715_4a-hurvitz.xml · nonDerivative · entry 1 Hurvitz Chaim · CIK 0001630542 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,812 F1 · price: The price reported in Column 4 is a weighted average price. The original Form 4 did not disclose the range of prices that the shares were purchased pursuant to this transaction. This Form 4/A is being filed to include such ranges. These shares were purchased in multiple transactions at prices ranging from $1.00 to $0.93. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 19:40 UTC |
Javitt Daniel C.10% owner
|
Salecommon stock | 49,200 | $1.01 | $49,509.96 |
DisclosureSEC source: 0000880984-22-000014 · primary_doc.xml · nonDerivative · entry 1 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 9,823,701 F1 · kind: Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022. F2 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| October 21, 2022 Filed Nov 21, 2022 17:58 UTC |
Hurvitz ChaimDirector
|
GrantEmployee Stock Option · Derivative | 162,660 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000950142-22-003233 · es220307158_4-hurvitz.xml · derivative · entry 6 Hurvitz Chaim · CIK 0001630542 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,083 Underlying: Common Stock · 162,660 shares Expires 2032-10-21 F4 · price: Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for the Issuer. F4 · derivative.exercise_date: Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for the Issuer. Read SEC document |
| October 21, 2022 Filed Nov 22, 2022 17:44 UTC |
Flynn Patrick JohnDirector
|
GrantEmployee Stock Option · Derivative | 162,660 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000950142-22-003242 · es220307154_4-flynnp.xml · derivative · entry 1 Flynn Patrick John · CIK 0001864871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,660 Underlying: Common Stock · 162,660 shares Expires 2032-10-21 F1 · price: Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc. F1 · derivative.exercise_date: Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc. Read SEC document |
| October 21, 2022 Filed Nov 22, 2022 17:46 UTC |
Gorovitz AaronDirector
|
GrantEmployee Stock Option · Derivative | 162,660 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000950142-22-003244 · es220307157_4-gorovitz.xml · derivative · entry 1 Gorovitz Aaron · CIK 0001864536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,660 Underlying: Common Stock · 162,660 shares Expires 2032-10-21 F1 · price: Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc. F1 · derivative.exercise_date: Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc. Read SEC document |
| October 21, 2022 Filed Nov 22, 2022 17:45 UTC |
Glied SharonDirector
|
GrantEmployee Stock Option · Derivative | 162,660 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000950142-22-003243 · es220307156_4-glied.xml · derivative · entry 1 Glied Sharon · CIK 0001864538 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,097 Underlying: Common Stock · 162,660 shares Expires 2032-10-21 F1 · price: Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc. F1 · derivative.exercise_date: Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 17:43 UTC |
Javitt Daniel C.10% owner
|
SaleCommon Stock | 784,063 | $1.01 | $791,433.19 |
DisclosureSEC source: 0000880984-22-000009 · primary_doc.xml · nonDerivative · entry 1 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 9,872,901 F1 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 17:06 UTC |
Javitt Daniel C.10% owner
|
GiftCommon Stock | 2,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000880984-22-000008 · primary_doc.xml · nonDerivative · entry 1 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 10,656,964 F1 · shares: Shares were gifted to a charitable remainder unitrust. F2 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| June 07, 2022 Filed Jun 7, 2022 20:11 UTC |
Javitt Daniel C.10% owner
|
SaleCommon Stock | 86,459 | $0.65 | $55,861.16 |
DisclosureSEC source: 0000880984-22-000007 · primary_doc.xml · nonDerivative · entry 3 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 12,656,964 F1 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| June 06, 2022 Filed Jun 7, 2022 20:11 UTC |
Javitt Daniel C.10% owner
|
SaleCommon Stock | 115,657 | $0.67 | $76,946.60 |
DisclosureSEC source: 0000880984-22-000007 · primary_doc.xml · nonDerivative · entry 2 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 12,743,423 F1 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 20:11 UTC |
Javitt Daniel C.10% owner
|
SaleCommon Stock | 243,596 | $0.70 | $171,101.83 |
DisclosureSEC source: 0000880984-22-000007 · primary_doc.xml · nonDerivative · entry 1 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 12,859,080 F1 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 09:46 UTC Amendment |
Javitt Jonathan CDirector · Chief Scientist · 10% owner
|
PurchaseCommon Stock | 100,000 | $0.58 | $58,000.00 |
DisclosureSEC source: 0000921895-22-001874 · form4a13398002_06022022.xml · nonDerivative · entry 1 Javitt Jonathan C · CIK 0001303782 · Director · Chief Scientist · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,332 Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 08:55 UTC |
Javitt Jonathan CDirector · Chief Scientist · 10% owner
|
PurchaseCommon Stock | 100,000 | $58.00 | $5,800,000.00 |
DisclosureSEC source: 0000921895-22-001872 · form413398002_06012022.xml · nonDerivative · entry 1 Javitt Jonathan C · CIK 0001303782 · Director · Chief Scientist · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,332 Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 16:04 UTC |
Besthof RobertInterim CEO
|
GrantEmployee Stock Option · Derivative | 100,000 | $2.61 Strike: $2.61 | $261,000.00 |
DisclosureSEC source: 0000950142-22-000997 · es220233694_4-besthof.xml · derivative · entry 1 Besthof Robert · CIK 0001864650 · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,200 Underlying: Common Stock · 100,000 shares Expires 2032-03-08 F1 · derivative.exercise_date: Options issued under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on March 8, 2023, generally subject to the Reporting Person's continued service for NRX Pharmaceuticals, Inc. Read SEC document |
| September 15, 2021 Filed Nov 2, 2021 16:04 UTC |
Besthof RobertChief Comm. & Patient Officer
|
SaleCommon Stock | 40,000 | $11.76 | $470,400.00 |
DisclosureSEC source: 0000950142-21-003503 · es210197021_4-besthof.xml · nonDerivative · entry 2 Besthof Robert · CIK 0001864650 · Chief Comm. & Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,710 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.